JAIDS Journal of Acquired Immune Deficiency Syndromes
30:541–544 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 30, 2002

Author Index

Aaby P, 342
Abebe A, 359
Adler B, 177
Aebi C, 288
Aguilera A, 366
Akincigil A, 429
Aklilu M, 359, 463
Alary M, 514
Albu JB, 379
Amiel C, 294
Anastos K, 401
Anderson RM, 167
Andersson S, 342
Archer H, 260
Aris E, 119
Ariyoshi K, 342
Arroyo JA, 457
Asaad R, 33

Ba L, 133
Bahr GM, 294
Baiget M, 457
Bajaria SH, 41
Bakari M, 119
Balfour HH Jr, 154
Bang H, 316
Barass C, 413
Benito R, 366
Bentata M, 81
Beyene A, 359
Biberfeld G, 119
Blanchard J, 133
Blanchette C, 514
Blattner W, 88
Blum RA, 261
Boenim W, 503
Bosch R, 130
Boulanger E, 478
Brand R, 177
Bremer J, 88
Broliden K, 413
Brooks RG, 351
Brown AE, 503
Bruno R, 535
Buhles W, 392
Burbano X, 260
Burger DM, 324
Burke J, 401
Busch MP, 527
Buss NE, 460
Bussaratid V, 503
Bwayo JJ, 69, 413
Byerer C, 493
Byers R Jr, 240

Caballero E, 366
Calderón E, 366
Calza L, 258
Cardon B, 478
Carli T, 533
Carmona A, 105
Carranza C, 33
Casey S, 177
Castelo A, 527
Cauda R, 369
Caylà JA, 105
Celentano DD, 306, 493
Chaddic C, 503
Chaifongsri R, 493
Chale S, 119
Chan KJ, 440
Chantawuttinan T, 410
Charubala R, 9
Chen ISY, 1
Chen Z, 133
Cherry CL, 271
Cheseaux J-J, 288
Chiu C, 1
Chiu J, 503
Choo PW, 27
Choopanya K, 240, 248
Chow Y-H, 1
Claessens C, 514
Clerici M, 413
Clinical Epidemiology Group from the French Hospital Database on HIV, 81
Cloyd M, 41
Cohen MH, 401
Coley J, 316
Colson AE, 27
Cook JA, 401
Corsi P, 533
Costagliola D, 81
Coutinho R, 359, 463
Crockett LK, 351
Crystal S, 429
Curtis R, 95

Dabtham K, 410
Danner S, 167
Darcissac E, 294
De La Tribonnière X, 294
De Lazzari E, 364
De Wolf F, 167
Deloumeaux J, 81
Des Jarlais D, 240
Des Jarlais DC, 95, 448
Des Jarlais DC, S1, S30, S73
Descamps D, 59
Devito C, 413
Di Pietro M, 533
Diaz RM, S118
Diaz RS, 527
Dilley JW, 177
Doll LS, S130
Domenech M, 457
Domingo P, 457
Donnelly CA, 167
Durier C, 59

Eirós JM, 366
Eke A, S30, S51
Engelson ES, 379
Evans S, 154

Falusi OM, 191
Fawzi WW, 316
Ferguson NM, 167
Fernandez MI, 311
Filho OF, 527
Filice C, 535
Filice G, 535
Filler SG, 154
Fisher M, 392
Flandre P, 59
Fleming D, 522
Flores SA, S30, S73, S106
Fonck K, 69
Fontanet AL, 359, 463
Fordyce EJ, 111
Forlenza S, 111
Foroohar M, 1
Fowler MG, 216, 230
Fox-Tierney R, 311
Fraser C, 167
Freedberg KA, 421

Friedberg D, 392
Friedman SR, 95, 448

Gahan ME, 271
Galicier L, 478
Gallagher B, 111
García de Olalla P, 105
García F, 364
García J, 366
Gascon RL, 146
Gatell JM, 364
Gazzard BG, 278, 460
Gérard L, 478
Geskus R, 463
Gettie A, 133
Ghani AC, 167
Giami A, 187
Gianesin M, 458
Gill CJ, 485
Glesby MJ, 379
Gnehm H, 288
Gold J, 131
Goldie SJ, 421
Goldman M, 154
Golmard J-L, 263
Gonnelli A, 533
González M, 536
Gonzalez OY, 363
González-Lahoz J, 65
González-Santos P, 536
Gorbach SL, 485
Goudsmit J, 167, 463
Grabar S, 81
Grey D, 401
Griffith JL, 485
Grosskurth H, 73
Guelar A, 105
Gyarmathy VA, 448

Hadjivassiliou M, 257
Hagos M, 463
Hailu B, 463
Hankins C, 514
Harding E, 342
Harrigan RP, 159
Hatzakis A, 124
Haubrich R, 154
Hawkins D, 410
Hayes R, 73
Heath KV, 440
Hecht FM, 146
Hedges LV, S8, S62, S73, S94, S106, S118
Hekster YA, 324
Henderson EE, 9
Herndier BG, 146
Heymsfield SB, 379
Hill AM, 410
Hillyer G, 88
Hinkula J, 413
HIV/AIDS Prevention Research Synthesis Project Team, S15
Ho DD, 133
Hogg RS, 159, 440
Hollinger FB, 88
Holmgren B, 342
Holtgrave DR, S130
Homan JW, 9
Hopkins RS, 351
Hoy JF, 271
Hsieh Y-H, 537
Hu DJ, 240, 248
Huang Y, 133
Hugen PWH, 324
Hughes M, 130
Hugonnet S, 73
Hunter DJ, 316
Hurley LB, 471
Hylton K, S51

Ickovics JR, 311

Jacobson D, 485
Jani AA, 351
Jenkins RA, 503
Johnson WD, S8, S30, S62, S73, S106, S118
Joly V, 59
Jose Miguez M, 260
Josiah R, 119
Jotterand V, 288
Jovanovich JF, 363

Kahn JO, 146
Kanshana S, 410
Kapiga SH, 316
Kaul R, 69, 413
Kawichai S, 493
Kay L, S30
Keli F, 69
Keller MJ, 27
Kennedy GE, S56
Kessler HA, 191, 458
Khamboonruang C, 493, 503
Kiama P, 413
Kiiti N, S51
Kimani J, 69, 413
Kimmel AD, 421
Kind C, 288
Kirschner D, 41
Kirstein L, 401
Kitayaporn D, 240, 248
Kittikraisak W, 248
Klein D, 471
Kliphuis A, 463
Klokke A, 73
Knobel H, 105
Koenig LJ, 311
Koopmans PP, 324
Kotler DP, 379
Kottiri BJ, 95
Krol A, 463
Kufera J, 88
Kumar S, 458
Kuppermann B, 392
Kyriakis KP, 257

Lackritz EM, 196
Lai H, 306
Lai S, 306
Lalezari J, 392
LaLiberte N, 335
Lallemand F, 187
Lalonde R, 392
Lancar R, 81
Landay A, 458
Lange CG, 33
Lange J, 167
Langebeek N, 324
Laranjeira RR, 527
Larocca LM, 369
LaRussa P, 88
Launay O, 59
Lazarevitch Claire-Anne Wyler, 288
Lederman MM, 33
Leone G, 369
Lew J, 88
Lewin SR, 271
Li K, 335
Li Y, 131
Liberti T, 351
Lieb S, 351
Lihatsh T, 177
Lima JAC, 306
Linard F, 187
Lindley J, 392
Lipman PD, S30
Lopalco L, 413
López-Colomés JL, 105
Losina E, 421
Lucia MB, 369
Luo C, 196
Lyles CM, S15

MacDonald KS, 69
Madero JS, 33
Magao P, 119
Magder LS, 88
Magiorkinis E, 124
Magiorkinis G, 124
Maillard A, 478
Mallet A, 263
Mallolas J, 364
Mandalia S, 278
Manfredi R, 258
Márquez M, 536
Martelli CMT, 527
Martinand-Mari C, 9
Martín-Carbonero L, 65
Martínez E, 364
Mastro TD, 240, 248
Matheron S, 392, 478
Mayers DL, 363
McArthur JC, 271
McFarland W, 177
McGrath MS, 146

McIntosh K, 88
McLaughlin G, 351
McSpiritt E, 429
Medvik K, 33
Meignin V, 478
Mekonnen Y, 359
Mendes de Leon CF, 191
Mendez D, 379
Meng Q, 306
Messele T, 359
Mhalu F, 119
Miedema F, 463
Miller CL, 335
Miller M, 448
Minkoff HL, 311
Miró JM, 364
Mock PA, 240, 248
Modesitt S, 522
Mofenson LM, 200, 216
Montaner JSG, 159, 440
Mooser V, 288
Moreno A, 364
Morgan PA, 503
Moses S, 69
Mosha F, 73
Moshi A, 119
Mouton Y, 294
Moyle GJ, 410, 460
Msamanga GI, 316
Mugeye K, 73
Mugusi F, 119
Mullen PD, S30, S62, S94
Munderi P, 200
Musher DM, 363

Nadal D, 288
Nadler JP, 351
Nagelkerke NJ, 69
Naksrisook S, 503
Narváez AB, 146
Nash D, 111
Natpratan C, 493
Ndeki L, 73
Neaigus A, 95, 448
Needle R, S73
Nelson KE, 306, 493
Nelson MR, 278
Nelson R, 240
Nerad JL, 191
Neumann MS, S30, S106
Newell ML, 230
Ngugi EN, 69
Nguyen L, 240, 248
Nicod P, 288
Nieto L, 392
Nitayaphan S, 503
Nolan M, 216
Norman L, S73
Norman LR, S118
Núñez M, 65

O'Brien K, 522
O'Shaughnessy MV, 159, 335, 440
Obee EM, 130
Oksenhendler E, 478
Ortiz de Lejarazu R, 366

Pacheko C, 33
Palacio H, 401
Palacios R, 536
Pallangyo K, 119
Pallangyo N, 119
Paltiel AD, 421
Pang S, 1
Paparizos VA, 257
Papastamopoulos V, 257
Paraskevis D, 124
Parent R, 514
Park N-H, 1
Peduzzi C, 533
Peersman G, S15, S30, S51, S56, S106
Pereira da Silva W, 527
Pérez-Cuevas B, 364
Pérez-Olmeda M, 65
Peter JB, 261
Pettus PT, 27
Pfleiderer W, 9
Phonrat B, 503
Piconi S, 413
Pitisuttithum P, 503
Pitt J, 88
Platt R, 27
Plummer F, 413
Plummer FA, 69
Pocock N, 131
Pollakis G, 463
Pozniak AL, 278
Proia LA, 191
Pulvirenti JJ, 458
Puoti M, 535

Quesenberry CP Jr, 471
Quint L, 478

Ramirez G, S62, S73, S118
Ramírez G, S94
Reichenbach NL, 9
Reiss P, 167
Rich S, 191
Richardson J, 401
Rinaldi J, 177
Rinke de Wit TF, 359, 463
Ríos P, 65
Rodés B, 366
Rodriguez C, 366
Rogers TJ, 9
Romano L, 533
Ronald AR, 69
Rose A, 522
Ross D, 73
Royce RA, 311
Rozenbaum W, 187
Rudin C, 288
Ruiz J, 536
Rutella S, 369
Rutherford G, S56

Sabatino J, 177
Sabino EC, 527
Sacchi P, 535
Salhi Y, 187
Sambamoorthi U, 429
Sambeat MA, 457
Sanders E, 359, 463
Sandstrom E, 119
Santos J, 536
Sax PE, 27
Schechter MT, 335
Schim van der Loeff M, 342
Schuurman R, 324
Scofield JM, S134
Seage III GR, 421
Seco L, 457
Semaan S, S1, S8, S15, S30, S51, S62, S73, S106, S118
Sha BE, 191
Shaffer N, 196
Sherlock CH, 159
Shor-Posner G, 260
Sidney S, 471
Sill A, 88
Singer J, 440
Singh TP, 111
Sirichthaporn P, 410
Sirijongdee N, 503
Skinner S, 485
Skowron G, 130
Smith KY, 191, 458
Smith RA, S134
Sogolow E, S8, S15, S30, S62, S73, S94, S106, S118
Somburanasin P, 410
Sontirat A, 503
Soriano V, 65, 366
Sornsathapornkul P, 503
Spiegelman D, 316
Spittal PM, 335
Srisaengchai P, 503
Srithanaviboonchai K, 493
Stavrianeas NG, 257
Steele AD, 9
Stempien MJ, 392
Strathdee S, 306
Street JC, 130
Strouse D, S15, S30, S94
Subbarao S, 240, 248
Suhadolnik RJ, 9
Supajatura V, 410
Sutton MA, 392
Suwanarach C, 503
Sweat MD, S51, S73, S118
Swindells S, 154

Talwani R, 191
Tantipiwatanaskul P, 493
Tassie J-M, 81

Temmerman M, 69
Thai AIDS Vaccine Evaluation Group, 503
Thapinta D, 503
The HIV Research Network, 21
The SurvUDI Working Group, 514
Thompson D, 351
Thongchareon P, 503
Todd J, 73
Tong W, 306
Toro C, 366
Torriani FJ, 392
Tortajada C, 364
Trabattoni D, 413
Tsegaye A, 359, 463
Turchi MD, 527
Tuset C, 366
Tyndall MW, 159, 335

Valdez H, 33
Valdivielso P, 536
Valensin PE, 533
Valls E, 364
Van Beneden CA, 522
van Griensven F, 240, 248
van Leusen R, 324
Van Syoc R, 392
Vandamme A-M, 124
Vanichseni S, 240, 248
Vastrup P, 342
Vazquez G, 457
Vella S, 369
Venturi G, 533
Vergu E, 263
Vidal V, 294
Virkud VM, 351
Vithayasai V, 410
Vlahov D, 306

Walmsley S, 392
Walsh JC, 278
Wang J, 379
Wattanatchariya N, 410
Webb G, 41
Wei OL-C, 1
Wesselingh SL, 271
West KC, 351
Whittle H, 342
Wilson IB, 485
Wilson T, 401
Wilson TE, 311
Wolday D, 463
Wongkamhaeng S, 503
Wood E, 159
Woods WJ, 177

Xie Y, 1

Yang OO, 1
Yip B, 159
Young M, 401
Young NL, 240, 248
Yu D, 1
Yusem S, 522

Zackin R, 154
Zazzi M, 533
Zhang J-y, 1
Zhang R, 146
Zhao X, 133
Zomer B, 324

JAIDS Journal of Acquired Immune Deficiency Syndromes
30:545–553 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 30, 2002

Subject Index

A/E/G recombination, analysis of, 124
Aboriginal population, adolescent female, sexual and drug vulnerabilities of with injection drug use among, 335
Adherence
  comparison of measurement methods for, 324
  prenatal and postpartum, 311
  in survival, 105
  virologic rebound on HAART and, 278
Adipose redistribution, antiretroviral therapy patterns and, 440
Adolescence
  HIV prevention interventions and sexual risk behaviors among, S94
  sexual and drug vulnerabilities among injection drugs users in, 335
Adverse drug effects, male sexual dysfunction in, 27
Africa
  declining prevalence of HIV and syphilis among women attending antenatal care clinics in, 359
  dropouts in follow-up study involving voluntary counseling and HIV testing in, 119
  HIV incidence in stable sexual partnerships in, 73
  increased HTLV-1 prevalence among HIV-2 infected women in, 342
  primary HIV-1 subtype C infection in, 463
  reduced HIV risk-taking and low HIV incidence in after STD prevention trial, 69
  viral load among HIV-1 seropositive women in, 316
AIDS agenda, in resource-poor countries, 196
AIDS-associated Kaposi sarcoma, response to HAART (letter), 257
AIDS-defining illnesses, combination antiretroviral therapy and survival rates with, 111
AIDS progression, in HIV-1 infected subjects with known date of infection, 81
AIDS-related behavior change, theories of, S1
Antenatal care clinics, in declining prevalence of HIV-1 infection and syphilis among women in Ethiopia, 359
Antiretroviral therapy
  absence of exon 8 mutation of *LMNA* gene in lipodystrophy associated with (letter), 457
  adherence to in survival rates, 105
  CCR5 and CXCR4 expression after (letter), 458
  combination, survival rates with, 111
  computed tomographic assessment of coronary artery disease in HIV-infected men receiving, 191
  coronary heart disease risk with, 471
  discordant CD4 cell count increases relative to plasma viral load in, 159
  efficacy and safety of atorvastatin for hypercholesterolemia associated with (letter), 536
  health-related quality of life and, 485
  HIV-1 progression to AIDS with, 81
  hyperlipidemia in children treated with, 288
  impact of viral replication suppression by on immune function and phenotype, 33
  in vitro and in vivo modulation of MDR1/P-glycoprotein with, 369
  lack of therapeutic benefit of hydroxyurea in (letter), 363
  limited impact of in thrombocytopenia (letter), 260
  lopinavir/ritonavir treatment after failure of multiple regimens of (letter), 533
  low resistance in virologic rebound on, 278
  magnitude of reduction in HIV-1 RNA with, 59
  male sexual dysfunction associated with, 27
  mental health quality of life with, 401
  modifying incidence and outcome of visceral leishmaniasis in HIV-infected patients (letter), 364
  patterns of in HIV-associated morphologic and lipid abnormalities, 440
  in prevention of perinatal HIV-1 transmission, 216
  resistance characteristics of HIV strains in predicting response to, 263
  response of AIDS-associated Kaposi sarcoma to (letter), 257
  safety of in perinatal transmission prevention, 200
  severe transaminase elevation after introduction of, 65
  sexual dysfunction with, 187
  systemic non-Hodgkin lymphoma with effective HIV RNA suppression in, 478
  utilization of, 21
  viral replication under, 167
Apoptosis
  associated increased HLA-DR expression on peripheral blood monocytes in primary HIV infection, 146
  homing-induced, in $CD4^+$ T-cell depletion, 41
Asia
  genetic analysis of HIV-1 strains among injection drug users in, 248
  higher viral loads and other risk factors associated with HIV-1 seroconversion among injection drug users in, 240
Atherosclerosis, with HAART in children, 288
Atorvastatin, efficacy and safety of for hypercholesterolemia with antiretroviral therapy (letter), 536

Bangkok
  genetic analysis of HIV-1 strains among injection drug users in, 248
  higher viral loads and other risk factors associated with HIV-1 seroconversion among injection drug users in, 240

Bathhouses, sexual risk behaviors in, 522
Behavior change
in adolescents with HIV prevention interventions, S94
U.S.-based trials of interventions for, S30
Behavioral HIV prevention interventions, effects of on sexual risk behaviors of adolescents, S94
β-chemokines, in clinical tolerance to murabutide in HIV-1-infected patients, 294
Biases, in antiretroviral therapy efficacy, 59
Body composition, human growth hormone effect on in HIV infection, 379
Bone mineral density, abnormalities in with HIV infection (letter), 131
Brazil, HIV-1 genetic subtyping among cocaine users in, 527
Breastfeeding
in HIV-1 transmission in resource-limited settings, 230
preventing AIDS transmission through in resource-poor countries, 196

Canada, HIV transmission among injection drug users in, 514
Candida esophagitis, chronic HIV-1 mortality and, 421
Candidiasis, HIV-1 viral load predicting risk for, 154
Cardiac abnormalities, protease inhibitor-related, 306
Cardiac function, with protease inhibitor use, 306
Case-control study, of HIV/AIDS-related death in Florida, 351
CCR5 expression
after HAART (letter), 458
in SHIV infection in Asian Macaques, 133
CD4 cell counts
discordant increases in relative to plasma viral load, 159
health-related quality of life and, 485
population baseline, in methodologic approach (letter), 130
preventable opportunistic infections and, 421
CD4 cells
apoptosis of associated increased HLA-DR expression on peripheral blood monocytes in primary HIV infection, 146
depletion of with increased HLA-DR expression on peripheral blood monocytes in primary HIV infection, 146
dynamics of in HIV-1 disease progression, 41
gp120-independent HIV-1 infection of, 1
CD4 epithelial cells, gp120-independent HIV-1 infection of, 1
CD4+ lymphocytopenia, in acute SHIV in Asian Macaques, 133
$CD4^+$ nadir, with HAART, 33
CEM T cells, EGFP-expressing viruses from, 1
Chemokines
$2\text{–}5A^{N6B}$ enhanced expression of, 9
in clinical tolerance to murabutide in HIV-1-infected patients, 294
Children, hyperlipidemia with HAART in, 288
Clinical trials
of human growth hormone for lipodystrophy in HIV infection, 379
magnitude of reduction in HIV-1 RNA in, 59
Cocaine users, HIV-1 genetic subtyping among, 527
Cochrane Collaborative Review Group, in HIV infection and AIDS, S56
Cohort study
of dropouts from study involving counseling and HIV testing, 119
of progression to AIDS in HIV-1 infected subjects with known date of infection, 81
Collaborative review, of HIV/AIDS prevention, S56
Combination antiretroviral therapy
survival rates and, 111
viral replication under, 167
Commercial sex workers
reduced HIV risk-taking in after risk-reduction counseling, 69
in Thailand, changing faces of (letter), 537
Community study, of HIV-2-infected men and women in rural Guinea-Bissau, 342
Computed tomography, electron beam, in assessing coronary artery disease in HIV-infected men receiving antiretroviral therapy, 191
Coronary artery disease, assessment of in HIV-infected men receiving antiretroviral therapy, 191
Coronary heart disease, protease inhibitors and increased risk of, 471
Cost of care, for HIV-1 infected patients, 21
Counseling, dropouts in study involving, 119
Crack cocaine users, HIV-1 genetic subtyping among, 527
CRF-1_AE, reanalysis of, 124
Cross-clade HIV neutralization, by IgA in exposed uninfected subjects, 413
CXCR4 expression, after HAART (letter), 458
Cytomegalovirus, chronic HIV-1 mortality and, 421
Cytomegalovirus retinitis, oral valganciclovir maintenance treatment of, 392

Delayed type hypersensitivity, with HAART, 33
Depression, with highly active antiretroviral therapy, 401
Developing countries
acquiring and reviewing HIV risk reduction intervention studies in, S51
breastfeeding in HIV-1 transmission in, 230
prevention of mother-to-child transmission in, 196
volunteer recruitment for multisite preventive HIV vaccine trial in, 503
Diaries, in protease inhibitor adherence measurement, 324
Diastolic dysfunction, with protease inhibitor use, 306
Dideoxynucleosides, reduced mitochondrial DNA in subcutaneous fat with exposure to, 271
Discordant couples, HIV incidence in, 73
Disease progression
from 1992 to 1999 in HIV-1 infected subjects with known date of infection, 81
dynamics of naive and memory $CD4^+$ T cells in, 41
Doxorubicin, in vitro and in vivo modulation of MDR1/P-glycoprotein with, 369
Drug risk behaviors, U.S.-based trials of interventions for, S30
Drug tolerance, in HIV-1-infected patients, 294
Drug users
HIV-1 genetic subtyping among, 527
HIV and hepatitis risk among, 448

Echocardiography
abnormalities of with protease inhibitor use, 306
Electron beam computed tomography, in assessing coronary artery disease in HIV-infected men receiving antiretroviral therapy, 191
Electronic monitoring, of protease inhibitor adherence, 324
Enhanced green fluorescent protein (EGFP), inserted into HIV-1 virus strain, 1
Epidemiologic surveillance, for HIV transmission among injection drug users in Canada, 514
Erratum
"Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia" (29:388–395), 368
"Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy" (2001:26(4):315–9), 462
"Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in *Erythrocebus patas* monkeys" (29:343–349), 368
Ethical issues, in volunteer recruitment for multisite preventive HIV vaccine trial, 503
Ethiopia
declining prevalence of HIV and syphilis among women attending antenatal care clinics in, 359
primary HIV-1 subtype C infection in, 463
Ethnicity, in HIV infection among injection drug users, 95
Evaluation studies
for HIV prevention, S62
of HIV prevention for men having sex with men, S118
scope, methods, and study classification results of, S15
Evidence-based health care, international collaborative review of, S56
Exon 8 mutation, in combination antiretroviral therapy-associated lipodystrophy (letter), 457
Exposed-uninfected subjects, HIV-1 cross-clade neutralization by IgA in, 413

Fat accumulation, human growth hormone for, 379
Florida, case-control study of HIV/AIDS clinics in, 351

Ganciclovir, for cytomegalovirus retinitis, 392
Gay men
HIV prevalence and sexual behaviors of in urban bathhouses, 522
HIV prevention research on, S118
sexual behavior changes in, 177
Gender prevalence, of HTLV-1 in rural Guinea-Bissau, 342
Genetic analysis, of HIV-1 strains among injection drug users in Bangkok, 248
Genetic diversity, HIV-1 incidence and among cocaine users in Brazil, 527
Genotype
in HAART drug resistance and virologic rebound, 278
mutations of with nelfinavir-based regimens (letter), 258
role of in severe transaminase elevation after introduction of HAART, 65
Genotypic testing, for resistance characteristics of viral strains in HIV infection, 263
Glucose tolerance, in lipodystrophy in HIV infection, 379
gp120-independent infection, of CD4 cells, 1
Growth hormone, for lipodystrophy in HIV infection, 379
Guinea-Bissau, increased HTLV-1 prevalence among HIV-2 infected women in, 342

Health-related quality of life, HIV viral loads, CD4 counts, and HAART use related to, 485
Health services utilization, in HIV-1 infected patients, 21
Hepatitis virus
chronic, hepatocellular carcinoma in HIV-infected patients with (letter), 535
hepatitis B risk among noninjecting heroin users, 448
hepatitis C
genotype of in severe transaminase elevation after antiretroviral therapy, 65
risk of among noninjecting heroin users, 448
Hepatocellular carcinoma, in HIV-infected patients with chronic hepatitis (letter), 535
Heroin addicts, HIV and hepatitis risk among, 448
Heterosexual populations, HIV prevention intervention research on, S106
Highly active antiretroviral therapy (HAART)
adherence to in survival rates, 105
CCR5 and CXCR4 expression after (letter), 458
$CD4^+$ T-cell dynamics and disease progression with, 41
health-related quality of life and, 485
HIV-1 progression to AIDS with, 81
hyperlipidemia in children treated with, 288
impact of viral replication suppression by on immune function and phenotype, 33
in vitro and in vivo modulation of MDR1/P-glycoprotein with, 369
lack of therapeutic benefit of adding hydroxyurea to (letter), 363
limited impact of in thrombocytopenia (letter), 260
low resistance in virologic rebound on, 278
mental health quality of life with, 401
modifying incidence and outcome of visceral leishmaniasis in HIV-infected patients (letter), 364
response of AIDS-associated Kaposi sarcoma to (letter), 257
severe transaminase elevation after introduction of, 65
sexual dysfunction with, 187
systemic non-Hodgkin lymphoma with effective HIV RNA suppression in, 478
HIV-1 genetic subtyping, among cocaine users in Brazil, 527
HIV-1 incidence/prevalence
among injection drug users in Bangkok, 248
genetic diversity and among cocaine users in Brazil, 527
risk factors for among injection drug users in Bangkok, 240
HIV-1 infection
circulating recombinant form A/E, reanalysis of, 124
clinical tolerance to murabutide in, 294
cross-clade neutralization of by IgA in exposed uninfected subjects, 413
gp120-independent, 1
preventable opportunistic infections and mortality with, 421
HIV-2 infection, increased HTLV-1 prevalence with, 342
HIV-1 replication, morphine-potentiated, inhibition of, 9

HIV-1 RNA
in HIV-1 seropositive women in Tanzania, 316
magnitude of reduction in, 59
preventable opportunistic infections and, 421
HIV-1 seroconversion, higher viral loads and other risk factors associated with among injection drug users, 240
HIV-1 strains, genetic analysis of among injection drug users in Bangkok, 248
HIV-1 subtypes
subtype C in Ethiopia, 463
subtype E, reanalysis of, 124
HIV-1 transmission, risk factors for during lactation, 230
HIV-1 viral load, predicting risk for opportunistic infection, 154
HIV-1 viral phenotype, perinatal HIV transmission and, 88
HIV/AIDS clinics, case-control study from, 351
HIV/AIDS epidemic, among commercial sex workers in Thailand (letter), 537
HIV/AIDS Prevention Research Synthesis Project
implications of for federal HIV prevention policy, S130
implications of for state, territorial, and local health departments, S134
HIV-associated abnormalities, antiretroviral therapy patterns and, 440
HIV drug resistance, in predicting antiretoviral therapy response, 263
HIV genotype mutations, with nelfinavir-based regimens (letter), 258
HIV neutralization, by IgA in exposed uninfected subjects, 413
HIV prevalence/incidence
among injection drug users in Canada, 514
among women attending antenatal care clinics, 359
reduced after risk-reduction counseling, 69
in stable sexual partnerships in Tanzania, 73
voluntary HIV counseling and testing at northern Thailand district hospital from 1995–1999 and, 493
HIV prevention
acquiring and reviewing non-U.S.-based studies of, S51
effects of on sexual risk behaviors of adolescents, S94
federal policy for, S130
HIV/AIDS Prevention Research Synthesis Project implications for policy on, S130
meta-analysis of effect of on sex behavior of drug users, S73
meta-analysis of research on among heterosexuals in United States, S106
reduced HIV risk-taking and, 69
U.S.-based trials of risk reduction interventions for, S30
HIV prevention research
cumulative knowledge or accumulating studies in, S1
for men having sex with men, S118
protocols for analytic aspects of systematic review of, S62
scope, methods, and study classification results of, S15
theoretical issues in synthesizing, S8
HIV risk/risk behavior
among noninjecting heroin users, 448
intervention studies for, non-U.S.-based, S51
meta-analysis of effects of prevention interventions on, S73
HIV RNA suppression, systemic non-Hodgkin lymphoma with, 478
HIV seropositivity
mental health quality of life with highly active antiretroviral therapy in women with, 401
in urban bathhouses, 522
HIV testing
dropouts in study involving, 119
at northern Thailand district hospital from 1995–1999, 493
HIV transmission, among injection drug users in eastern central Canada, 514
HIV vaccine trial, volunteer recruitment for in Thailand, 503
HIV viral loads, monitoring in United States (letter), 261
HIV wasting syndrome, survival rates with combination therapy for, 111
HLA-DR expression, on peripheral blood monocytes in HIV infected subjects, 146
Homing-induced apoptosis, in $CD4^+$ T-cell depletion, 41
Homosexual men
HIV prevalence among in urban bathhouses, 522
sexual behavior changes, 177
Hospital admission, of HIV-1 infected patients, 21
Host factors, in HIV-1 disease progression, 41
HTLV-1
clinical impact of in Spain (letter), 366
increased prevalence of among HIV-2-infected women in rural Guinea-Bissau, 342
HVIp24, with HAART, 33
Hydroxyurea, lack of therapeutic benefit of (letter), 363
Hypercholersterolemia, efficacy and safety of atorvastatin for with antiretroviral therapy (letter), 536
Hyperlipidemia, in HIV-infected children on HAART, 288

Immune function
HAART-suppressed viral replication and, 33
in HIV-1 transmission during lactation, 230
Immune response, to murabutide in HIV-1-infected patients, 294
Immunoglobulin A, in cross-clad HIV-1-specific neutralization, 413
Immunotherapy, clinical tolerance to in HIV-1-infected patients, 294
In-depth interviews, in protease inhibitor adherence measurement, 324
Incubation duration, of HIV-1 with known date of infection, 81
Infants, safety of antiretroviral prophylaxis in, 200
Injection drug users
continuing HIV transmission among, 514
genetic analysis of HIV-1 strains among, 248
higher viral loads and other risk factors associated with HIV-1 seroconversion among, 240
meta-analysis of HIV prevention intervention effects on sex behaviors of, S73
racial/ethnic differences in HIV infection among, 95
sexual and drug vulnerabilities among, 335
Interferon, $2\text{–}5A^{N6B}$ enhanced expression of, 9
International collaborative systematic reviews, of HIV/AIDS prevention, S56
Intervention studies
in federal HIV prevention policy, S130
of HIV prevention among heterosexuals in United States, S106

for men having sex with men, S118
protocols for analysis of, S62
Interventions
for HIV risk reduction, non-U.S.-based studies of, S51
research on implementation of, S1
for risk reduction, U.S.-based, S30

Kaposi's sarcoma
AIDS-associated, response to HAART (letter), 257
survival rates with combination therapy for, 111
Kenya, reduced HIV risk-taking and low HIV incidence in after STD prevention trial, 69

Lactate, inhibited mitochondrial DNA in with dideoxynucleoside exposure, 271
Lamivudine, safety of efficacy of in preventing vertical HIV transmission, 410
Left ventricular morphology, with protease inhibitor use, 306
Leishmaniasis, visceral, HAART effect on incidence and outcome of (letter), 364
Letters to editor
Absence of mutation in exon 8 of the *LMNA* gene in combination antiretroviral therapy-associated partial lipodystrophy, 457
Bone mineral density abnormalities in patients with HIV infection, 131
CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART), 458
Changing faces of commercial sex in Thailand: implications for the HIV/AIDS epidemic, 537
Clinical impact of HTLV-1 infection in Spain: implications for public health and mandatory screening, 366
Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy, 536
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue, 535
Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients, 364
HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options, 258
The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART), 363
Limited impact of highly active antiretroviral therapy in thrombocytopenia, 260
Methodologic approach used by Skowron et al., 130
Methodologic approach used by Skowron et al.: response to, 130
Monitoring HIV viral loads in the United States: recent trends and methodologies, 261
Prevastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy, 460
Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone, 257
Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice, 533
Limit of quantification, suppression of HIV-1 RNA levels below, 59
Lipids
abnormalities of and antiretroviral therapy patterns, 440
accumulation of in HIV infection, 379
with HAART in children, 288
Lipodystrophy
absence of exon 8 mutation of *LMNA* gene in (letter), 457
antiretroviral therapy patterns and, 440
recombinant human growth hormone effect on, 379
Liposomal doxorubicin, in vitro and in vivo modulation of MDR1/P-glycoprotein with, 369
Liver toxicity, hepatitis C virus genotype and after introduction of HAART, 65
LMNA gene mutation, in combination antiretroviral therapy-associated lipodystrophy (letter), 457
Local health departments, HIV/AIDS Prevention Research Synthesis Project implications for, S134
Lopinavir/ritonavir, with failure of multiple antiretroviral regimens (letter), 533
Lymphoma, systemic non-Hodgkin, in HIV-infected patients with effective HIV RNA suppression, 478
Lymphoproliferation, with HAART, 33

Macaques, vaginally transmissible subtype-C, CCR5-tropic SHIV in, 133
Magnitude of reduction, in HIV-1 RNA levels in clinical trials, 59
Male sexual dysfunction, with antiretroviral therapy, 27
Mathematical model
of dynamics of naive and memory $CD4^+$ T cells in HIV-1 disease progression, 41
for resistance characteristics of viral strains in HIV infection, 263
of viral replication under combination antiretroviral therapy, 167
MDR1/P-glycoprotein, in vitro and in vivo modulation of, 369
Medicaid, zidovudine used during pregnancy among women on, 429
Medication Events Monitoring System (MEMS)
for prenatal and postpartum zidovudine adherence among pregnant women, 311
of protease inhibitor adherence, 324
Memory T cells, dynamics of in HIV-1 disease progression, 41
Mental health quality of life, with highly active antiretroviral therapy, 401
Meta-analysis
of behavioral HIV prevention intervention effects on sexual risk behaviors, S94
of HIV prevention intervention effect on sex behavior of drug users, S73
of HIV prevention intervention research for heterosexuals in United States, S106
of HIV prevention research, S62

of HIV prevention research for men having sex with men, S118
logic of, S1
Methodology
based on population baseline viral load and CD4 count (letter), 130
in HIV viral load monitoring in United States (letter), 261
Mitochondrial DNA, reduced numbers of in subcutaneous fat with dideoxynucleoside exposure, 271
Monocyte chemotactic protein-1, 2–5A^{N6B} enhanced expression of, 9
Morphine, in HIV-1 replication in peripheral blood mononuclear cells, inhibition of, 9
Mortality rate, prediction of from case-control study of public HIV/AIDS clinics, 351
Mother-to-child transmission
in breastfeeding in resource-limited settings, 230
prevention of in comprehensive AIDS agenda in resource-poor countries, 196
safety of saquinavir/zidovudine/lamivudine therapy to prevent, 410
Motivation, for participation in preventive HIV vaccine trials, 503
MT-2 assay, HIV-1 viral phenotype in and perinatal transmission, 88
Multidrug resistance, P-glycoprotein in, 369
Murabutide, tolerance of in HIV-1-infected patients, 294
Mycobacterium avium complex, chronic HIV-1 mortality and, 421
Myocardial infarction, protease inhibitors and increased risk of, 471

Naive CD4$^+$ T cells, dynamics of in HIV-1 disease progression, 41
National Alliance of State and Territorial AIDS Directors, HIV/AIDS Prevention Research Synthesis Project implications for, S134
National policy, HIV/AIDS Prevention Research Synthesis Project implications for, S130
Needle exchange programs, for injection drug users in Canada, 514
Nelfinavir, HIV genotype mutations with (letter), 258
Neuropsychological factors, in changing sexual behavior among gay men, 177
Nevirapine
perinatal transmission and resistance to, 216
safety of in HIV-infected pregnant women and infants, 200
New York City, survival rates in era of combination antiretroviral therapy in, 111
Noninjecting heroin users, HIV and hepatitis B and C virus risk in, 448
Nuclease-resistant 2–5A agonist, in inhibition of morphine-potentiated HIV-1 replication in PBMCs, 9
Nucleoside analog reverse transcriptase inhibitors, safety of in HIV-infected pregnant women and infants, 200
Nurse reporting, of protease inhibitor adherence, 324

Opportunistic infections
HIV-1 viral load predicting risk for, 154
oral valganciclovir for, 392
preventable, HIV-1 RNA and CD4 cell counts in, 421
Outcomes
operational definitions of, S62
research on measures of, S1
Outpatient health care utilization, by HIV-1 infected patients, 21

P-glycoprotein, in multidrug resistance, 369
Perinatal transmission
antiretroviral prophylaxis of and antiretroviral resistance in, 216
HIV-1 viral phenotype associated with, 88
safety of antiretroviral prophylaxis of, 200
Peripheral blood monocytes, increase HLA-DR expression on in primary HIV infection, 146
Peripheral blood mononuclear cells, inhibition of morphine-potentiated HIV-1 replication in, 9
Pharmacoepidemiology, of male sexual dysfunction, 27
Pharmacokinetics, of saquinavir/zidovudine/lamivudine therapy during pregnancy, 410
Pharmacy refill data, in protease inhibitor adherence measurement, 324
Phenotype
in HAART drug resistance and virologic rebound, 278
HAART-suppressed viral replication and, 33
perinatal HIV transmission and, 88
testing of for resistance characteristics of viral strains in HIV infection, 263
Phylogenetic analysis, of HIV-1 circulating recombinant form A/E, 124
Phylogenetic clusters, among injection drug users in Bangkok, 248
Physician adherence assessment, in protease inhibitor adherence measurement, 324
Pill count, in protease inhibitor adherence measurement, 324
Plasma concentrations, of protease inhibitors, adherence measurement and, 324
Plasma viral load, discordant CD4 cell count increases relative to, 159
Pneumocystis carinii pneumonia
chronic HIV-1 mortality and, 421
survival rates with combination therapy for, 111
Police officers, in study involving counseling and HIV testing, dropouts in, 119
Policy, HIV/AIDS Prevention Research Synthesis Project and, S130
Population-based studies, dropouts from, 119
Pregnancy
declining HIV infection and syphilis prevalence during with antenatal care, 359
safety of antiretroviral prophylaxis in, 200
safety of saquinavir/zidovudine/lamivudine therapy during, 410
zidovudine adherence during, 311
zidovudine use during, 429
Prenatal care, zidovudine use during, 429
Prevalence
decline in among young women in antenatal care clinics in Addis Ababa, 359
of HTLV-1 among HIV-2 infected women and men in rural Guinea-Bissau, 342

Prevastatin, protease inhibitor exposure and virologic efficacy with (letter), 460
Prevention interventions
effects of on sexual risk behaviors of adolescents, S94
international collaborative reviews of, S56
for men having sex with men, evaluation of, S118
meta-analysis of effects of on sex behaviors of drug users, S73
meta-analysis of research on among heterosexuals in United States, S106
for mother-to-child transmission in resource-poor countries, 196
for perinatal HIV-1 transmission, 216
for perinatal HIV transmission, 200
reduced HIV risk-taking and low HIV incidence after, 69
safety of saquinavir/zidovudine/lamivudine therapy in, 410
for sexual transmission among gay men, 177
U.S.-based trials of risk reduction interventions for, S30
Prevention policy, HIV/AIDS Prevention Research Synthesis Project implications for, S130
Prevention research
cumulative knowledge or accumulating studies in, S1
for men having sex with men, S118
non-U.S.-based, acquiring and reviewing, S51
scope, methods, and study classification results of, S15
theoretical issues in synthesizing, S8
Prevention Research Synthesis Project, implications of for state, local, and territorial health departments, S134
Program evaluation
for HIV prevention, S62
of HIV prevention for men having sex with men, S118
Progressors, with HAART, $CD4^+$ T-cell dynamics in, 41
Protease inhibitors
comparison of adherence measurement methods for, 324
coronary heart disease risk with, 471
electron beam computed tomography for assessing coronary artery disease in HIV-infected men receiving, 191
HIV-associated morphologic and lipid abnormalities and, 440
hyperlipidemia in children treated with, 288
left ventricular morphologic changes and diastolic dysfunction with, 306
male sexual dysfunction associated with, 27
prevastatin and exposure to (letter), 460
sexual dysfunction with, 187
Protocols, for systematic review of HIV prevention research, S62
Psychiatry, in changing sexual behavior among gay men, 177
Psychosocial factors, in changing sexual behavior among gay men, 177
Public health, HTLV-1 impact on (letter), 366
Pulmonary tuberculosis, survival rates with combination therapy for, 111

Quality of life
with highly active antiretroviral therapy, 401
HIV viral loads, CD4 counts, and HAART use related to, 485
with lipodystrophy in HIV infection, 379
Questionnaires, in protease inhibitor adherence measurement, 324

Racial differences, in HIV infection among injection drug users, 95
Randomized controlled trials
of HIV prevention for men having sex with men, S118
protocols for analysis of, S62
RANTES, 2–$5A^{N6B}$ enhanced expression of, 9
Recombinant human growth hormone, in visceral fat accumulation treatment, 379
Recombination, reanalysis of, 124
Research
on HIV prevention, S1
theoretical issues in synthesizing, S8
Research methods, HIV prevention, S15
Research participation, volunteer recruitment for in Thailand, 503
Research synthesis
in HIV prevention research, S8
implications of for federal HIV prevention policy, S130
scope, methods, and study classification results of, S15
Resistance
antiretroviral prophylaxis of perinatal HIV-1 transmission and, 216
in predicting antiretroviral therapy response in HIV infection, 263
testing for in measuring protease inhibitor adherence, 324
virologic rebound on HAART and, 278
Resource-limited settings, breastfeeding in HIV-1 transmission in, 230
Resource use, by HIV-1 infected patients, 21
Retinitis, cytomegalovirus, oral valganciclovir maintenance treatment of, 392
Risk behaviors/factors
of adolescents, effects of behavioral HIV prevention interventions on, S94
among injection drug users in Canada, 514
among young female drug users, 335
associated with HIV-1 seroconversion, 240
in HIV-1 transmission during lactation, 230
in HIV infection among injection drug users, 95
meta-analysis of effects of prevention interventions on, S73
in stable sexual partnerships in Tanzania, 73
Risk modification, with risk-reduction counseling, 69
Risk networks, racial/ethnic differences in HIV infection among injection drug users and, 95
Risk reduction interventions
non-U.S.-based studies of, S51
U.S.-based trials of, S30
Ritonavir, with failure of multiple antiretroviral regimens (letter), 533
Rural areas, increased HTLV-1 prevalence among HIV-2 infected women in, 342

Salmonella septicemia, survival rates with combination therapy for, 111
Saquinavir, safety of efficacy of in preventing vertical HIV transmission, 410
Screening, mandatory, HTLV-1 impact on (letter), 366
Self-reporting, of protease inhibitor adherence, 324
Sentinel surveillance, of HIV infection and syphilis prevalence among pregnant women in Ethiopia, 359

Seroconversion
higher viral loads and other risk factors associated with among injection drug users, 240
in stable sexual partnerships in Tanzania, 73
Seronegative individuals, HIV-1 cross-clade neutralization by IgA in, 413
Seropositivity, study withdrawal and, 119
Sex clubs, sexual risk behaviors in, 522
Sex workers, reduced HIV risk-taking in after risk-reduction counseling, 69
Sexual dysfunction
in ambulatory HIV-infected men receiving HAART, 187
with antiretroviral therapy, 27
Sexual partnerships, stable, HIV incidence in, 73
Sexual risk behaviors
of adolescents, effects of behavioral HIV prevention interventions on, S94
among gay male repeat HIV testers, 177
among heterosexual adult populations in United States, S106
among young female drug users, 335
meta-analysis of HIV prevention intervention effects on, S73
in urban bathhouse during HIV epidemic, 522
U.S.-based trials of interventions for, S30
Sexual transmission, prevention of among gay men, 177
Sexually transmitted disease
among heterosexual adult populations in United States, S106
prevention trials of, reduced HIV risk-taking and low HIV incidence after, 69
Simian/human immunodeficiency virus (SHIV), subtype C, CCR5-tropic, in Asian Macaques, 133
South America, HIV-1 genetic subtyping among cocaine users in, 527
Southeast Asia
genetic analysis of HIV-1 strains among injection drug users in, 248
higher viral loads and other risk factors associated with HIV-1 seroconversion among injection drug users in, 240
HIV/AIDS epidemic and changing faces of commercial sex in (letter), 537
voluntary HIV counseling and testing in, 493
volunteer recruitment for multisite preventive HIV vaccine trial in, 503
Spain, HTLV-1 impact in (letter), 366
Stable couples, HIV incidence in, 73
State health departments, HIV/AIDS Prevention Research Synthesis Project implications for, S134
Study classification, in HIV prevention research synthesis, S15
Study withdrawal, among police officers in Tanzania, 119
Subcutaneous fat, reduced mitochondrial DNA in with dideoxynucleoside exposure, 271
Substance abuse, meta-analysis of effects of prevention interventions on sex behaviors and, S73
Survival rates
adherence to HAART and, 105
with effective HIV RNA suppression, 478
in era of combination antiretroviral therapy, 111
Syphilis prevalence, among women attending antenatal care clinics, 359
Systematic reviews
acquiring and reviewing, S51
of HIV prevention research for men having sex with men, S118
international collaboration in, S56
protocols for analytic aspects of, S62
scope, methods, and study classification results of, S15

Tanzania
dropouts in follow-up study involving voluntary counseling and HIV testing in, 119
HIV incidence in stable sexual partnerships in, 73
viral load among HIV-1 seropositive women in, 316
Tattoos, HIV and hepatitis risk with, 448
3TC/zidovudine, perinatal transmission and resistance to, 216
Territorial health departments, HIV/AIDS Prevention Research Synthesis Project implications for, S134
Thailand
genetic analysis of HIV-1 strains among injection drug users in, 248
higher viral loads and other risk factors associated with HIV-1 seroconversion among injection drug users in, 240
HIV/AIDS epidemic and changing faces of commercial sex in (letter), 537
voluntary HIV counseling and testing in, 493
volunteer recruitment for multisite preventive HIV vaccine trial in, 503
Therapeutic drug monitoring, of protease inhibitor adherence, 324
Thrombocytopenia, limited impact of HAART in (letter), 260
Toxicity, of antiretroviral prophylaxis in HIV-infected pregnant women and infants, 200
Toxoplasmosis, chronic HIV-1 mortality and, 421
Transaminase, severe elevation of after introduction of antiretroviral therapy, 65
Transmission networks, among injection drug users in Bangkok, 248
Treatment failure, lopinavir/ritonavir treatment after (letter), 533
Trends, in HIV viral loads in United States (letter), 261
2–5A agonist, inhibiting morphine-potentiated HIV-1 replication in PBMCs, 9

United States, monitoring HIV viral loads in (letter), 261
U.S.-based trials, of HIV risk reduction interventions, S30

Vaccine trial, volunteer recruitment for in Thailand, 503
Vaginal transmission, of subtype C, CCR5-tropic SHIV in Asian Macaques, 133
Valganciclovir, safety study of for cytomegalovirus retinitis, 392
Vertical transmission
prevention of in comprehensive AIDS agenda in resource-poor countries, 196
saquinavir/zidovudine/lamivudine therapy in prevention of, 410

Viral factors
in HIV-1 disease progression, 41
in HIV-1 transmission during lactation, 230
Viral load
associated with HIV-1 seroconversion, 240
discordant CD4 cell count increases relative to, 159
health-related quality of life and, 485
in HIV-1 seropositive women in Tanzania, 316
with HIV-1 subtype C infection in Ethiopia, 463
monitoring of in United States (letter), 261
population baseline, in methodologic approach (letter), 130
predicting risk for opportunistic infection, 154
prevastatin and exposure to (letter), 460
Viral phenotype, perinatal HIV transmission and, 88
Viral replication
under combination antiretroviral therapy, 167
suppression of by HAART, 33
Viral strains, resistance characteristics of in predicting antiretroviral therapy response in HIV infection, 263
Virologic rebound, low antiretroviral drug resistance and, 278
Visceral fat accumulation, recombinant human growth hormone effect on, 379
Voluntary counseling, at northern Thailand district hospital from 1995–1999, 493
Volunteer recruitment, for multisite phase I/II HIV preventive vaccine trial in Thailand, 503

Women
declining prevalence of HIV-1 infection and syphilis among in Ethiopia, 359
HIV-seropositive, mental health quality of life with HAART in, 401
increased HTLV-1 prevalence with HIV-2 infection among, 342
prenatal and postpartum zidovudine adherence among, 311
sexual and drug vulnerabilities of with injection drug use among, 335
viral load and HIV-1 seropositivity among, 316
zidovudine used during pregnancy among, 429

Zidovudine
perinatal transmission and resistance to, 216
during pregnancy among HIV-infected women on Medicaid, 429
prenatal and postpartum adherence to among pregnant women with HIV, 311
safety and efficacy of in preventing vertical HIV transmission, 410
safety of in HIV-infected pregnant women and infants, 200